In general, over 20% of AD patients are hypertensive and receive different modalities of hypotensive agents, including central α-adrenergic agonists, vasodilators, diuretics, nitrates, nitrites, phosphodiesterase inhibitors, calcium channel blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, mineralcorticoid (aldosterone) receptor antagonists, renin inhibitors, and other plural miscellaneous compounds (Table 2). This evidence concerns the gene ACE and Alzheimer disease.